Corbus Pharmaceuticals Holdings (CRBP) Given News Impact Score of 0.10
Headlines about Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corbus Pharmaceuticals Holdings earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.4524836507376 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- Corbus Pharmaceuticals : to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD (4-traders.com)
- Corbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD (finance.yahoo.com)
- A Look From Top to Bottom on Corbus Pharmaceuticals Holdings Inc (CRBP) – Hayden Business Journal (haydenbusinessjournal.com)
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) noted a price change of 2.19% and Neuralstem, Inc. (CUR) closes with … – Stocks Gallery (stocksgallery.com)
Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded up 4.03% during midday trading on Thursday, hitting $7.75. 773,767 shares of the company were exchanged. The stock’s market capitalization is $389.21 million. Corbus Pharmaceuticals Holdings has a 52-week low of $3.73 and a 52-week high of $10.78. The company has a 50-day moving average price of $6.24 and a 200-day moving average price of $7.04.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.04. The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.50 million. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 1,001.77%. On average, analysts forecast that Corbus Pharmaceuticals Holdings will post ($0.66) EPS for the current year.
A number of research firms have recently issued reports on CRBP. BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Cantor Fitzgerald set a $24.00 target price on shares of Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $20.50.
About Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.